$VOR:NASDAQ · Vor Biopharma Inc.
Conviction from: NASDAQ
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases.
More about this company
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Not currently held by tracked 13F filers — this page aggregates activist, insider, politician and research activity.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-04-21 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |
| 2026-04-15 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |
| 2026-04-10 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |
| 2026-04-08 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |
| 2026-04-01 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |
| 2026-03-16 | SCHEDULE 13D/A | RA CAPITAL MANAGEMENT, L.P. | 19.9% | High | filing |